Welcome to J.B.CHEMICALS AND PHARMACEUTICALS LTD.

Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally. Today, JBCPL exports to over 30 countries across the world and earns more than half its revenue from its international business. 

JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules. 

JBCPL has its headquarters in India’s financial capital, Mumbai. With a domestic sales force of 1,000 people, 17 internationally approved state of the art manufacturing units, a Research and Development Centre, and subsidiaries abroad, the organisation is continually enhancing value for its shareholders. 

In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL.

The Indian pharmaceutical market has been growing at an annual compounded rate of 15% and is valued at Rs. 55,000 crores ($10 billion). This surge can be attributed to higher private healthcare spending by Indians, greater penetration of pharmaceutical companies into the country’s interior, and an increasing awareness of chronic issues like cardiac disease and diabetes. According to a report by consultancy group McKinsey, pharmaceutical growth in India will triple to Rs. 1,00,000 crores (US$20 billion) by 2015 when India will be one of the world’s top 10 pharmaceutical markets. 

JBCPL is among the top 40 pharmaceutical companies in the local market and the top 20 pharmaceutical companies with India and exports business. 

JBCPL has three divisions 

• Unique division is the general division with major brands in Gastro, Cardiac and Pain management
• JB division focusing on Gastro and Pain market
• Femident division focusing on Dental and Gynaec segments

JBCPL has a presence in 22 major therapeutic groups with 108 brands in the domestic market. Some of JBCPL’s leading brands in India are in Amoebicides, Anti-peptic ulcerants, NSAID, Cardiac care, Quinolones and Antacids. They are among the top 300 brands in terms of units in the Indian pharmaceutical market

• Metrogyl (Metronidazole)
• Nicardia (Nifedipine)
• Rantac (Ranitidine)
• Dicloran (Diclofenac Sodium)
• OF (Ofloxacin)
• Cilacar (Cilnidipine)
• Zecuf herbal

Some of these brands have achieved brand leadership in their segments

• Nicardia in Nifidipine market
• Rantac-D in Ranitidine + Domperidone market
• Metrogyl IV in Metronidazole IV market
• Metrogyl in Amoebecides market
• Nor-Metrogyl in Norfloxacin + Metronidazole market
• Nimek – Spas in Dicyclo + Nimesulide market

Below are brands that are top ranking in therapeutic segments:

• Rantac 3rd in Ranitidine market
• Rantac MPS 6th in Antacid market
• Motiza 5th in Itopride market
• Varitide 5th in Octreotide Acetate market
• OF susp. 5th in Ofloxacin Oral liquid market
• OF-M susp. 3rd in Ofloxacin + Metronidazole Liquid market
• Colopeg 3rd in Oral Saline Preperations
• Manogyl 4th in Irrigating Solutions market

In India we aim to:

• Increase our depth and introduce new products in a few selected therapeutic groups
• Improve our geographical reach by increasing our penetration in tier 2 markets
• Increase our presence in the hospital segment
• Manage the life cycle of established products

Read more